



| | |
|------------------------|----------------------------------|
| Company | Starpharma Holdings Limited |
| Code | SPL |
| Meeting | AGM |
| Date | 20 November 2020 |
| Venue | Virtual |
| Proxy Collector | Donald Pitkethly (a shareholder) |

| | |
|--|---|
| Number attendees at meeting | unknown |
| Number of holdings represented by ASA | 20 (30% increase on the preceding year) |
| Value of proxies | \$556k |
| Number of shares represented by ASA | 400k (30% increase on the preceding year) |
| Market capitalisation | \$564M |
| Were proxies voted? | Yes, on a poll. All ASA proxies voted FOR the motions |
| Pre-AGM Meeting? | No |

“Long term prospects outstanding” - Chairman

A lengthy two-hour meeting. One hour devoted to the Chairman’s address and a technical update from the CEO, Dr Jackie Farley, then a brief period on the motions and an hour of questions. There was no video of the directors which seemed reasonable as they were at different locations. Slides from the CEO’s presentation were very detailed and required a full screen and complete concentration for a layman to follow. Questions were either covered in the CEO’s presentation, grouped for those on the same topic or paraphrased due to the large number and the lengthy session.

All motions were passed with a large majority and no issues raised from the audience.

FY20 was a successful year with revenue up 142% although the loss for the year was \$14.6m due to the large R&D expenditure. The cash balance at 30 June was \$30.1m.

Staff including the CEO worked at home if possible, during the COVID lockdown. There were no salary increases nor bonuses paid to conserve cash. Directors salaries seem modest considering to the challenges and progress during the year.

No issues were raised from the audience on Starpharma’s recent \$45m share placement at \$1.50/share which was oversubscribed. Retailers shareholders who represent 40% of shareholders

weren't left out as they could purchase up to \$30k also at \$1.50/share. The fund raising has left the company in a safe financial position with >\$70M of funds on-hand for work on 'Viraleze' (a preventative COVID nasal spray) and other development programs.

The share price gained 3.7% on the day. FY21 should see substantial progress.